Higher expression of circulating miR-182 as a novel biomarker for breast cancer

Oncology Letters

Volumn 6, Issue 6, 2013, Pages 1681-1686

  Wang, Ping Yu ^a   Gong, Hai Tao ^c   Li, Bao Feng ^d   Lv, Chun Lei ^d   Wang, Huan Tai ^c   Zhou, Hui Hui ^e   Li, Xin Xin ^b   Xie, Shu Yang ^b   Jiang, Bao Fa ^a  

^a SHANDONG UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

^c WEIFANG MEDICAL UNIVERSITY   (China)

^d Shandong China Traditional Medical Affiliated Hospital   (China)

^e QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Breast cancer; Circulating miRNAs; Diagnosis; Gene expression; miR 182

Indexed keywords

ESTROGEN RECEPTOR; MICRORNA 182; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION;

EID: 84886782280     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1593     Document Type: Article

References (40)

1. Sariego J: Breast cancer in the young patient. Am Surg 76: 1397-1400, 2010.
2. Anders CK and Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9 (Suppl 2): S73-S81, 2009.
3. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006.
4. Stefani G and Slack FJ: Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 9: 219-230, 2008.
5. Di Leva G, Piovan C, Gasparini P, et al: Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet 9: e1003311, 2013.
6. Ozgün A, Karagoz B, Bilgi O, Tuncel T, Baloglu H and Kandemir EG: MicroRNA-21 as an indicator of aggressive phenotype in breast cancer. Onkologie 36: 115-118, 2013.
7. Han M, Liu M, Wang Y, et al: Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol Cell Biochem 363: 427-436, 2012.
8. Yu SJ, Hu JY, Kuang XY, et al: MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res 19: 1389-1399, 2013.
9. Castilla MÁ, Díaz-Martín J, Sarrió D, et al: MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One 7: e47709, 2012.
10. Sun X, Qin S, Fan C, Xu C, Du N and Ren H: Let-7: a regulator of the ERα signaling pathway in human breast tumors and breast cancer stem cells. Oncol Rep 29: 2079-2087, 2013.
11. Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13-21, 2008.
12. Hunter MP, Ismail N, Zhang X, et al: Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e3694, 2008.
13. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
14. Zhu W, Qin W, Atasoy U and Sauter ER: Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2: 89, 2009.
15. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251: 499-505, 2010.
16. Schrauder MG, Strick R, Schulz-Wendtland R, et al: Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 7: e29770, 2012.
17. Wu AH, Vigen C, Razavi P, Tseng CC and Stancyzk FZ: Alcohol and breast cancer risk among Asian-American women in Los Angeles County. Breast Cancer Res 14: R151, 2012.
18. Shrubsole MJ, Gao YT, Dai Q, et al: Passive smoking and breast cancer risk among non-smoking Chinese women. Int J Cancer 110: 605-609, 2004.
19. Gammon MD, Eng SM, Teitelbaum SL, et al: Environmental tobacco smoke and breast cancer incidence. Environ Res 96: 176-185, 2004.
20. Chiang CH, Hou MF and Hung WC: Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys Acta 1830: 3067-3076, 2013.
21. Krishnan K, Steptoe AL, Martin HC, et al: MicroRNA-182-5p targets a network of genes involved in DNA repair. RNA 19: 230-242, 2013.
22. Cui X, Schiff R, Arpino G, Osborne CK and Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23: 7721-7735, 2005.
23. Diaz NM: Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer Control 8: 415-418, 2001.
24. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ and Kerin MJ: MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol 2009: 950201, 2009.
25. Xi Y, Nakajima G, Gavin E, et al: Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13: 1668-1674, 2007.
26. Li J, Smyth P, Flavin R, et al: Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 7: 36, 2007.
27. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
28. Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
29. Mattie MD, Benz CC, Bowers J, et al: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5: 24, 2006.
30. Zhong S, Chen Z, Xu J, Li W and Zhao J: Pre-mir-27a rs895819 polymorphism and cancer risk: a meta-analysis. Mol Biol Rep 40: 3181-3186, 2013.
31. Pastrello C, Polesel J, Della Puppa L, Viel A and Maestro R: Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients. Carcinogenesis 31: 2124-2126, 2010.
32. Linhares JJ, Azevedo M Jr, Siufi AA, et al: Evaluation of single nucleotide polymorphisms in microRNAs (hsa-miR-196a2 rs11614913 C/T) from Brazilian women with breast cancer. BMC Med Genet 13: 119, 2012.
33. Moskwa P, Buffa FM, Pan Y, et al: miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41: 210-220, 2011.
34. Guttilla IK and White BA: Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 284: 23204-23216, 2009.
35. Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
36. Liu J, Mao Q, Liu Y, Hao X, Zhang S and Zhang J: Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res 25: 46-54, 2013.
37. Chen W, Cai F, Zhang B, Barekati Z and Zhong XY: The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol 34: 455-462, 2013.
38. Si H, Sun X, Chen Y, et al: Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 139: 223-229, 2013.
39. Osborne CK, Schiff R, Arpino G, Lee AS and Hilsenbeck VG: Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 14: 458-465, 2005.
40. Faheem M, Mahmood H, Khurram M, Qasim U and Irfan J: Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. Ecancermedicalscience 6: 283, 2012.